Szingapúr - angol - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human coagulation factor viii - injection, powder, lyophilized, for solution - 500iu/vial - human coagulation factor viii 500iu/vial

Málta - angol - Medicines Authority

biotest pharma gmbh landsteinerstrasse 5, 63303 dreieich, germany - factor viii, human - powder and solvent for solution for injection - factor viii, human 50 iu - antihemorrhagics

Málta - angol - Medicines Authority

biotest pharma gmbh landsteinerstrasse 5, 63303 dreieich, germany - factor viii, human - powder and solvent for solution for injection - factor viii, human 50 iu/ml - antihemorrhagics

Málta - angol - Medicines Authority

biotest pharma gmbh landsteinerstrasse 5, 63303 dreieich, germany - factor viii, human - powder and solvent for solution for injection - factor viii, human 100 iu/ml - antihemorrhagics

Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - nonacog alfa - hemophilia b - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor-ix deficiency).,

Európai Unió - angol - EMA (European Medicines Agency)

sanquin plasma products b.v. - human coagulation factor ix - hemophilia b - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).

Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - moroctocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor-viii deficiency). refacto af is appropriate for use in adults and children of all ages, including newborns. refacto af does not contain von-willebrand factor, and hence is not indicated in von-willebrand's disease.,

Európai Unió - angol - EMA (European Medicines Agency)

csl behring gmbh - lonoctocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).afstyla can be used for all age groups.

Európai Unió - angol - EMA (European Medicines Agency)

baxalta innovations gmbh - nonacog gamma - hemophilia b - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).

Egyesült Államok - angol - NLM (National Library of Medicine)

kvk-tech, inc. - phentermine hydrochloride (unii: 0k2i505otv) (phentermine - unii:c045tql4wp) - phentermine hydrochloride 8 mg - lomaira™ tablets are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity in patients with an initial body mass index greater than or equal to 30 kg/m 2 , or greater than or equal to 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). below is a chart of body mass index (bmi) based on various heights and weights. bmi is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters. body mass index (bmi), kg/m 2 the limited usefulness of agents of this class, including phentermine (see clinical pharmacology ), should be measured against possible risk factors inherent in their use such as those described below. • history of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • during or within 14 days following the administration of monoamine oxidase inhibitors • hyperthyroidism • glaucoma • agitated states • history of drug abuse • pregnancy (see precautions ) • nursing (see precautions ) • known hypersensitivity, or idiosyncrasy to the sympathomimetic amines phentermine is a schedule iv controlled substance. phentermine is related chemically and pharmacologically to the amphetamines. amphetamines and other stimulant drugs have been extensively abused and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. there are reports of patients who have increased the dosage of these drugs to many times than recommended. abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep eeg. manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. a severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.